

Asthma Indicators for LHIN 10: South East

Indicator	Asthma Indicators for LHIN 10: South East																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	36.03	39.48	39.34	38.57	39.77	40.66	42.61	42.97	41.33	40.47	42.66	49.76	48.85	50.55	54.92	52.23	52.48	53.49	52.29	60.38	61.69	59.46	63.80
2. PFT used for monitoring (% of prevalent asthma) [†]	9.28	8.26	8.11	7.64	7.12	6.61	6.97	6.15	5.95	5.62	5.30	5.27	5.16	5.09	5.35	5.41	5.64	5.15	5.25	5.58	5.77	6.05	6.23
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	57.53	56.15	53.63	53.52	53.00	53.22	52.59	50.34	50.68	50.68	50.75	50.06	49.56	49.42	50.19	50.32	50.96	51.11	49.58	49.50	48.62	45.54	43.61
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	65.20	64.09	61.43	60.52	59.23	57.51	55.07	52.07	51.61	50.87	50.18	48.76	46.16	46.16	46.10	45.62	44.22	45.05	41.54	30.68	30.00	27.77	26.94
5. ≥1 asthma ED visit (% of prevalent asthma)	5.13	4.87	4.38	4.22	3.87	3.54	2.95	3.19	2.84	2.94	2.96	2.85	2.36	2.23	1.92	1.81	1.64	1.73	1.47	1.56	1.49	1.39	1.49
6. ≥1 asthma physician office visit (% of prevalent asthma)	33.74	31.42	27.81	26.49	24.70	23.53	20.92	19.73	18.61	17.80	17.14	15.72	13.82	13.10	12.70	12.05	10.82	10.52	9.93	10.16	9.73	9.44	9.35
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	34.80	35.91	38.57	39.48	40.77	42.49	44.93	47.93	48.39	49.13	49.82	51.24	53.84	53.84	53.90	54.38	55.78	54.95	58.46	69.32	70.00	72.23	73.06
1-2	16.44	17.95	17.82	18.12	18.65	19.40	19.04	17.36	18.45	18.82	19.33	19.16	18.57	19.25	19.62	19.24	19.05	20.26	19.05	13.94	13.88	12.63	12.37
≥3	48.75	46.14	43.61	42.40	40.57	38.11	36.02	34.71	33.16	32.05	30.85	29.60	27.60	26.90	26.48	26.37	25.17	24.78	22.48	16.74	16.12	15.14	14.57

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.